Looking at harm minimisation

Naloxone, hazardous use of alcohol and treatment inequity: part two of our expert discussion of the latest in harm minimisation Why is the naloxone program not seeing wider take-up? Should pharmacists be able to inject buprenorphine? Should pharmacies be able to offer drug testing? Are pharmacies offering stigma-free methadone provision? Regular AJP contributor and leading addiction medicine

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Pharmacy needs retention plan
Next Employment reminder